Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) declared a dividend on Wednesday, February 26th, DividendData.Co.Uk reports. Shareholders of record on Thursday, March 20th will be paid a dividend of $0.48 per share on Thursday, May 1st. This represents a yield of 1.8%. The ex-dividend date is Thursday, March 20th. This is a 50.0% increase from Hikma Pharmaceuticals’s previous dividend of $0.32. The official announcement can be seen at this link.
Hikma Pharmaceuticals Price Performance
LON:HIK traded up GBX 22 ($0.29) during trading hours on Tuesday, hitting GBX 2,052 ($26.65). 76,300,625 shares of the stock traded hands, compared to its average volume of 3,417,024. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82. Hikma Pharmaceuticals has a 1 year low of GBX 1,750 ($22.73) and a 1 year high of GBX 2,360 ($30.65). The company has a market cap of £5.69 billion, a price-to-earnings ratio of 20.14, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. The stock has a 50 day moving average price of GBX 2,177.22 and a 200 day moving average price of GBX 2,014.40.
Analyst Ratings Changes
HIK has been the topic of several analyst reports. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Hikma Pharmaceuticals in a report on Friday, March 7th. Berenberg Bank reaffirmed a “buy” rating and set a GBX 2,560 ($33.25) price target on shares of Hikma Pharmaceuticals in a report on Monday, March 10th.
About Hikma Pharmaceuticals
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.
Featured Stories
- Five stocks we like better than Hikma Pharmaceuticals
- Most Volatile Stocks, What Investors Need to Know
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Must-Own Stocks to Build Wealth This Decade
- High Flyers: 3 Natural Gas Stocks for March 2022
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.